Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Mipomersen(Archived)

Mostafa Hamada  1 , Khashayar Farzam  2
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Mipomersen(Archived)

Mostafa Hamada et al.
Free Books & Documents

Excerpt

Mipomersen is no longer commercially available in the U.S. See the FDA website (https://www.accessdata.fda.gov/scripts/cder/daf/) for discontinued drugs.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Mostafa Hamada declares no relevant financial relationships with ineligible companies.

Disclosure: Khashayar Farzam declares no relevant financial relationships with ineligible companies.

References

    1. Goldberg AC. Novel therapies and new targets of treatment for familial hypercholesterolemia. J Clin Lipidol. 2010 Sep-Oct;4(5):350-6. - PubMed
    1. Wong E, Goldberg T. Mipomersen (kynamro): a novel antisense oligonucleotide inhibitor for the management of homozygous familial hypercholesterolemia. P T. 2014 Feb;39(2):119-22. - PMC - PubMed
    1. Parham JS, Goldberg AC. Mipomersen and its use in familial hypercholesterolemia. Expert Opin Pharmacother. 2019 Feb;20(2):127-131. - PMC - PubMed
    1. Crooke ST, Geary RS. Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B. Br J Clin Pharmacol. 2013 Aug;76(2):269-76. - PMC - PubMed
    1. Muscoli S, Ifrim M, Russo M, Candido F, Sanseviero A, Milite M, Di Luozzo M, Marchei M, Sangiorgi GM. Current Options and Future Perspectives in the Treatment of Dyslipidemia. J Clin Med. 2022 Aug 12;11(16) - PMC - PubMed

Publication types

LinkOut - more resources